Tilvestamab BGB149|cas:2226775-26-2|西域试剂

Tilvestamab BGB149,98.08%

产品编号：Bellancom-P99161| CAS NO：2226775-26-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99161	￥3500.00	杭州北京（现货）
Bellancom-P99161	￥8400.00	杭州北京（现货）
Bellancom-P99161	￥13450.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Tilvestamab BGB149

产品介绍

Tilvestamab (BGB149) 是一种人源化抗 AXL 抗体，阻断 AXL 介导的细胞信号传导。Tilvestamab 在体外能显著抑制 Gas6 刺激诱导的 AXL 激活，并抑制 786-0-Luc RCC 细胞中下游 AXL 的磷酸化。Tilvestamab可用于癌症，尤其是 AXL 过度表达肾细胞癌的研究。

生物活性

Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas.

体外研究

Tilvestamab (250 µM; 1 h) inhibits AXL phosphorylation in 786-0 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	786-0-Luc cells (Gas6- induced; Gas6 is a well characterized AXL ligand)
Concentration:	250 µM
Incubation Time:	1 h (pre-treat)
Result:	Drastically inhibited Gas6- induced AXL phosphorylation and decreased the level of pAKT.

体内研究
(In Vivo)

Tilvestamab (30 mg/kg; i.p.; twice a week) suppresses tumor growth by inhibiting AXL in orthotopic RCC model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c athymic nude mice (8-week-old; orthotopic RCC model).
Dosage:	30 mg/kg
Administration:	Intraperitoneal injection; twice a week
Result:	Significantly inhibited RCC growth down to about 1/3 of the volume.

体内研究

Tilvestamab (30 mg/kg; i.p.; twice a week) suppresses tumor growth by inhibiting AXL in orthotopic RCC model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c athymic nude mice (8-week-old; orthotopic RCC model).
Dosage:	30 mg/kg
Administration:	Intraperitoneal injection; twice a week
Result:	Significantly inhibited RCC growth down to about 1/3 of the volume.

体内研究

Tilvestamab (30 mg/kg; i.p.; twice a week) suppresses tumor growth by inhibiting AXL in orthotopic RCC model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c athymic nude mice (8-week-old; orthotopic RCC model).
Dosage:	30 mg/kg
Administration:	Intraperitoneal injection; twice a week
Result:	Significantly inhibited RCC growth down to about 1/3 of the volume.